Adele Gulfo serves as Mylan’s EVP & Chief Strategy Officer. Reporting directly to the CEO, she focuses on Mylan’s key growth drivers, including the company’s expansion in Latin America, the development and expansion of its global Specialty franchise and the development of global commercial strategies to maximize its upcoming launches of increasingly complex specialty products, such as biologics, injectables and respiratory therapies.

Previously, Gulfo served as President & GM of Pfizer’s U.S. Primary Care business unit, which included Commercial Operations and the Managed Markets organization for all of Pfizer’s Biopharmaceutical business units. Under her leadership, Pfizer’s U.S. Primary Care business generated more than $13 billion in revenue.

Earlier in her career at Pfizer, Gulfo was instrumental in the launch and commercial success of LIPITOR, which became the world’s best-selling medicine with peak revenues greater than $10B globally.
Immediately prior to joining Mylan, Gulfo served as President of Latin America in Pfizer’s Emerging Markets business unit. In this capacity, she led a team of more than 4,000 colleagues operating across approximately two dozen countries.

In 2012, under her leadership, the Latin American business achieved more than $3 billion in revenue, making it the largest revenue generator within the unit.

Trained as a scientist with experience in both operational and strategic roles, Gulfo serves as an advisor for Cleveland Clinic’s Innovation Center, Partners Healthcare and Springboard Life Sciences. She was recognized for work in developing medical and public-education campaigns that helped to establish the significance of lowering LDL cholesterol in preventing and managing heart disease, and has five patents.

She serves on the Board of Directors for Volunteers of America and the Committee of 200 (C200), an invitation-only membership organization of the world’s most successful women business leaders.